Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7489292 | 1.00 | POLB (0.62) | POLBSMN1; SMN2NPC1RAB9APSEN1 | |
| SCHEMBL31037789 | 1.00 | POLB (0.62) | POLBSMN1; SMN2NPC1RAB9APSEN1 | |
| SCHEMBL115923 | 1.00 | POLB (0.62) | POLBSMN1; SMN2NPC1RAB9APSEN1 | |
| SCHEMBL464289 | 1.00 | POLB (0.62) | POLBSMN1; SMN2NPC1RAB9APSEN1 | |
| SCHEMBL7016734 | 1.00 | POLB (0.62) | POLBSMN1; SMN2NPC1RAB9APSEN1 | |
| SCHEMBL71529 | 1.00 | POLB (0.62) | POLBSMN1; SMN2NPC1RAB9APSEN1 | |
| SCHEMBL29878 | 1.00 | POLB (0.62) | POLBSMN1; SMN2NPC1RAB9APSEN1 | |
| SCHEMBL28269 | 1.00 | POLB (0.62) | POLBSMN1; SMN2NPC1RAB9APSEN1 | |
| SCHEMBL23485199 | 0.90 | POLB (0.61) | POLBSMN1; SMN2NPC1RAB9APSEN1 | |
| SCHEMBL30564487 | 0.90 | POLB (0.61) | POLBSMN1; SMN2NPC1RAB9APSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3658235-A1 | DIMERIC PEPTIDE INHIBITORS OF APOPTOSIS PROTEINS | Hepagene Therapeutics, Inc. (VG) | 2020-06-03 | — | — | EP | disclosed |
| CN-110944719-A | Dimeric peptide inhibitors of apoptotic proteins | 合帕吉恩治疗公司 | 2020-03-31 | — | — | CN | disclosed |
| WO-2019023275-A1 | DIMERIC PEPTIDE INHIBITORS OF APOPTOSIS PROTEINS | HEPAGENE THERAPEUTICS, INC. (VG) | 2019-01-31 | — | — | WO | disclosed |
| EP-2867238-B1 | PHENYL AMINO PYRIMIDINE BICYCLIC COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2017-08-09 | — | — | EP | disclosed |
| US-9469609-B2 | Synthesis of pyrrolidine compounds | ZEALAND PHARMA A/S (DK) | 2016-10-18 | — | — | US | disclosed |
| US-20150322007-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2015-11-12 | — | — | US | disclosed |
| EP-2730572-B1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2015-09-16 | — | — | EP | disclosed |
| US-8927590-B2 | Synthesis of pyrrolidine compounds | ZEALAND PHARMA A/S (DK) | 2015-01-06 | — | — | US | disclosed |
| EP-2041138-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2730572-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | Sunshine Lake Pharma Co., Ltd (CN) | 2014-05-14 | — | — | EP | disclosed |
| US-5143935-A | Gastrointestinal disorders | TEIKOKU CHEMICAL INDUSTRY CO., LTD. (JP) | 1992-09-01 | — | — | US | disclosed |
| EP-0497895-A1 | METHOD OF INHIBITING THE TRANSPORT OF L-GLUTAMATE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1992-08-12 | — | — | EP | disclosed |
| EP-0481756-A2 | Benzamide derivatives | TEIKOKU CHEMICAL INDUSTRY CO., LTD. (JP) | 1992-04-22 | — | — | EP | disclosed |
| WO-1991006536-A1 | METHOD OF INHIBITING THE TRANSPORT OF L-GLUTAMATE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1991-05-16 | — | — | WO | disclosed |
| US-4912231-A | Reacting a proline derivative with an aromatic nucleophile in presence of a Lewis acid catalyst | E. R. SQUIBB & SONS, INC. (US) | 1990-03-27 | — | — | US | disclosed |
| EP-0346847-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-12-20 | — | — | EP | disclosed |
| US-4316906-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-02-23 | — | — | US | disclosed |
| US-4252943-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1981-02-24 | — | — | US | disclosed |
| US-4241076-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1980-12-23 | — | — | US | disclosed |
| US-4217359-A | HYPOTENSIVE | E. R. SQUIBB & SONS, INC. (US) | 1980-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322007-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | CPS1, DHPS, DDC | POLB 406/4885SMN1; SMN2 2087/4885NPC1 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.